Current Edition

Advancements

Advancements of Gene Editing Technologies(CRISPR/Cas9)

An Introduction to Gene Editing – CRISPR-Cas9 The dynamic promise of gene editing for humans is the ability to precisely manipulate the sequence of the …

Continue Reading →
assay

Horizon Discovery enters into agreement with Roche Diagnostics to support the development of immunohistochemistry assays for oncology

Horizon Discovery Group plc, a global leader in gene editing and gene modulation technologies, today announces that it has entered into an agreement with Roche …

Continue Reading →
biotech

Sphere Fluidics and Geneva Biotech receive Eurostars genome editing grant

Sphere Fluidics, a company providing single cell analysis systems underpinned by its patented picodroplet technology, and Geneva Biotech, an EMBL spin-out developing world-class viral and non-viral …

Continue Reading →
antibiotic

Locus Biosciences raises $19 million series A for CRISPR-Cas3 Antimicrobials

Locus Biosciences has closed $19 million in Series A funding led by venture capital firm ARTIS Ventures with additional financing from notable institutional investors Tencent …

Continue Reading →
CRISPR-Cas9

IDT Provides Optimized Conditions for HDR in CRISPR Editing

As an advocate for the genomics age, Integrated DNA Technologies (IDT), has published a new application note on optimization of CRISPR-Cas9 for homology-directed repair (HDR) …

Continue Reading →
drug discovery

Horizon Discovery’s Dharmacon introduces Edit-R CRISPRa reagent platform for genome-wide CRISPR activation

Horizon Discovery, a global leader in gene editing and gene modulation technologies, today announced the launch of its reagent platform for CRISPR activation (CRISPRa) from …

Continue Reading →